A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
Study sponsor: Zai Lab (Shanghai) Co., Ltd.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-09-03Actual
Enrollment · participants123Actual
Source updated2023-08-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.